Myasthenia Gravis (Immunology) - Drugs in Development, 2021
- $ 2000
- April 2024
- 283 pages
Leronlimab (PRO-##) is under development for the treatment for human immunodeficiency virus (HIV) infection, metastasis triple-negative breast cancer, HER2 positive metastatic breast cancer (MBC), glioblastoma, throat cancer, stomach cancer, testicular cancer, ovarian cancer, uterine cancer, bladder cancer, metastatic colorectal cancer, prostate cancer, non-alcoholic steatohepatitis (NASH), liver, lung, melanoma,gastric (stomach), pancreatic cancers and Coronavirus disease 2019 (COVID- ##). [...] It is in Phase II stage of development for the treatment of solid tumor cancers, including melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, testicular, ovarian, uterine, pancreas and bladder cancers in the United States.